Hoth Therapeutics (NASDAQ:HOTH) Stock Price Down 7.1%

Hoth Therapeutics, Inc. (NASDAQ:HOTH) was down 7.1% on Monday . The company traded as low as $1.67 and last traded at $1.71. Approximately 201,461 shares changed hands during mid-day trading, a decline of 80% from the average daily volume of 1,014,072 shares. The stock had previously closed at $1.84.

Hoth Therapeutics Stock Down 7.1 %

The firm has a market capitalization of $5.64 million, a price-to-earnings ratio of -0.27 and a beta of 0.47. The stock’s 50 day moving average price is $2.44 and its two-hundred day moving average price is $2.32.

Hoth Therapeutics (NASDAQ:HOTH) last posted its quarterly earnings results on Friday, August 11th. The company reported ($0.57) earnings per share for the quarter.

Hedge Funds Weigh In On Hoth Therapeutics

Several hedge funds have recently bought and sold shares of the business. Vanguard Group Inc. increased its position in Hoth Therapeutics by 23.2% during the third quarter. Vanguard Group Inc. now owns 942,305 shares of the company’s stock worth $328,000 after buying an additional 177,659 shares during the last quarter. Renaissance Technologies LLC grew its position in shares of Hoth Therapeutics by 77.9% in the second quarter. Renaissance Technologies LLC now owns 157,245 shares of the company’s stock valued at $66,000 after purchasing an additional 68,845 shares during the last quarter. Armistice Capital LLC acquired a new stake in shares of Hoth Therapeutics in the fourth quarter valued at about $1,092,000. Virtu Financial LLC grew its position in shares of Hoth Therapeutics by 453.2% in the second quarter. Virtu Financial LLC now owns 138,213 shares of the company’s stock valued at $58,000 after purchasing an additional 113,229 shares during the last quarter. Finally, Acadian Asset Management LLC acquired a new stake in shares of Hoth Therapeutics in the first quarter valued at about $80,000. 2.17% of the stock is owned by institutional investors and hedge funds.

Hoth Therapeutics Company Profile

Hoth Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It is involved in the development of HT-001, a topical formulation, which is in Phase II clinical trial for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-TBI to treat traumatic brain injury and ischemic stroke; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; HT-004 for treatment of asthma and allergies using inhalational administration; HT-003 for the treatment of acne and psoriasis, as well as inflammatory bowel diseases; and HT-002, a novel peptide for treating COVID-19.